1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > A Competitive Analysis of the Global Asthma and COPD Therapeutics Market : Novel Inhaler Devices and Formulations are Impetuses for Growth

Key Findings

•Chronic obstructive pulmonary disorder (COPD) is the third leading cause of death in the United States, and is in fourth place in Europe and the rest of the world.
•An estimated xxmillion people are affected by COPD globally. By 2020, COPD is projected to be the third leading cause of death globally.
•Limited communication between medical practitioners and patients limits early diagnosis of the disease.
•It is estimated that only xx% of smokers detect the onset of COPD symptoms and seek medical advice and treatment.
•Bronchodilators, anti-inflammatories, and combination therapies are prime segments used in evaluating asthma and COPD therapeutics.
•Combination therapies such as Symbicort Turbuhaler, Relvar Ellipta, and Anoro Ellipta show promising market acceptance due to increased clinical benefits of higher drug efficacy, especially in patients with increased disease severity.
•Bronchodilators are widely used to manage mild to moderate symptoms associated with COPD.
•Patent expiration of blockbuster drugs such as Advair (known as Seretide in the European Union) widen pipeline investment opportunities to meet therapeutic demand.

Asthma

•Teva Pharmaceuticals, AstraZeneca, Novartis, Merck & Co., and Boehringer Ingelheim are among the Tier I participants in this market.
•Upcoming drugs include:
oDuoResp Spiromax, an inhaled corticosteroid and long-acting beta2-adrenoceptor agonist combination therapy drug by Teva Pharmaceuticals (approved, pending launch).
oStriverdi Respimat (olodaterol), a bronchodilator by Boehringer Ingelheim (approved, pending launch).
oBenralizumab, a monoclonal antibody jointly being developed by MedImmune and AstraZeneca in Phase 3 trials. Benralizumab is bound to the interleukin-5 receptor (IL-5R?) and is being evaluated to help asthma control and reduce the onset of asthmatic attacks.
oNovartis’ QMF149 Twisthaler is under drug safety trial to assess its effect on asthma exacerbations, and is expected to arrive in the market by 2017.

COPD

•Striverdi Respimat is approved in the United Kingdom, Denmark, and Iceland based on results obtained from Phase 3 trials, which displayed remarkable improvements in lung functions with the use of the drug as an addition to the usual care drugs in COPD patients. The estimated launch in the United States and Japan is expected to be either in the last quarter of 2014 or the first quarter of 2015.
•GSK and Theravance’s jointly developed drug, GSK961081, is classified as a bifunctional molecule developed with muscarinic antagonist and ?2-agonist (MABA) properties to be used by COPD patients. It is in Phase 2 in Australia.

CEO’s Perspective

Development of innovative COPD therapeutics to check inflammations and exacerbations in patients will increase.
The patent expiry of blockbuster drugs such as Advair opens investment opportunities for strengthening pipeline portfolios to meet the rising drug demands.
Interest in developing combination therapies is growing because of their higher therapeutic efficacy.
The high economic burden due to the rise of COPD incidence creates tremendous investment opportunities.
Limited knowledge of the disease, limited drug classes, and an absence of a permanent cure increases investment interest in the market.

Table Of Contents

A Competitive Analysis of the Global Asthma and COPD Therapeutics Market : Novel Inhaler Devices and Formulations are Impetuses for Growth
Executive Summary
•Key Findings
•Key Findings—Asthma
•Key Findings—COPD
•Overview of Product Launches and Pipeline Development
•Key Companies to Watch
•CEO's Perspective
Methodology and Scope
Market Overview
•Market Overview—Segmentation
•Market Overview—Definitions
•Prevalence of Asthma by Country/Region
•Prevalence of COPD by Country/Region
Asthma and COPD Competitive Landscape
•Asthma Therapeutics Market—Marketed and Pipeline Products
•Asthma Therapeutics Market—Key Marketed Product Synopsis
•Asthma Therapeutics Market—Key Pipeline Product Synopsis
•COPD Therapeutics Market—Marketed and Pipeline Products
•COPD Therapeutics Market—Key Marketed Product Synopsis
•COPD Therapeutics Market—Key Pipeline Product Synopsis
Event Timelines
•Total Asthma and COPD Therapeutics Market—Projected Launch Timeline for Key Pipeline Drugs
•Pivotal Phase 3 Trials
•Estimated Product Launch Timeline—Striverdi Respimat for Asthma and COPD by Boehringer Ingelheim
•Estimated Product Launch Timeline—Quilizumab for Asthma by Genentech
•Estimated Product Launch Timeline—DuoResp Spiromax for Asthma and COPD by Teva Pharmaceuticals
•Estimated Product Launch Timeline—Incruse Ellipta (umeclidinium) for COPD by GSK
•Estimated Product Launch Timeline—Benralizumab for Asthma by AstraZeneca
•Patent Expiration Timeline
Product Dashboards—Marketed, Approved, and Phase 3 Products
•Seebri Breezhaler by Novartis
•Advair/Seretide by GSK
•Xolair by Genentech and Novartis
•Asmanex Twisthaler by Merck and Co.
•Spiriva by Boehringer Ingelheim
•AirFlu Sal/Forspiro by Sandoz (Novartis)
•Incruse Ellipta by GSK
•Benralizumab by AstraZeneca
•Bosatria by GSK
•PT003 by Pearl Therapeutics (AstraZeneca)
Conclusions
Appendix
The Frost and Sullivan Story

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025 Summary Atrial fibrillation (AF) is the most common cardiac arrhythmia and is a heart condition that causes an irregula ...

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025 Summary Venous thromboembolism (VTE) is a disease that includes a myriad of life-threatening disorders ranging from ...

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

Ulcerative Colitis: Kol Insight

September 2016 $ 8085

Hepatitis C: Kol Insight

September 2016 $ 8085

Download Unlimited Documents from Trusted Public Sources

Therapy Market and Hypertension Statistics in Asia and the US

  • November 2016
    26 pages
  • Therapy  

    Hypertension  

    Cardiovascular ...  

  • Asia  

    United States  

    Europe  

View report >

Therapy Market in the US - Forecast

  • November 2016
    6 pages
  • Therapy  

    Opioid  

  • United States  

View report >

Analgesic Market in the UK

  • November 2016
    10 pages
  • Analgesic  

  • United Kingdom  

View report >

Related Market Segments :

Therapy
Asthma

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.